Development of monitoring adverse events assciated with bone modifiers in patients cancer bone metastases

2017 Fiscal Year Final Research Report

• Project/Area Number: 15K08591
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Multi-year Fund
• Section: 一般
• Research Field: Applied pharmacology
• Research Institution: Kobe Gakuin University (2016-2017); Kyushu University (2015)
• Principal Investigator: IKESUE HIROAKI 神戸学院大学, 薬学研究科, 連携准教授 (60748010)
• Co-Investigator(Renkei-kenkyūsha): MASUDA Satohiro 九州大学, 大学病院, 教授 (90303825)
• Project Period (FY): 2015-04-01 – 2018-03-31
• Keywords: がん / 骨転移治療薬 / ゾレドロン酸 / デノスマブ / 腎機能

Outline of Final Research Achievements

We performed a retrospective cohort study to asses the risk factors of kidney injury in 236 patients receiving zoledronic acid. The incidence of kidney injury was 13%. The multivariate analysis showed that diabetes mellitus, baseline lower kidney function, and concomitant use of cisplatin were significant risk factors for kidney injury. In addition, we experienced a case of acute kidney injury in a patient with metastatic malignant melanoma, receiving dabrafenib/trametinib combination therapy. We also retrospectively analyzed risk factors of osteonecrosis of the jaw (ONJ) in 397 patients receiving zoledronic acid or denosumab. The incidence of ONJ was 6%. The multivariate analysis showed that denosumab, older age, and concomitant use of anti-angiogenetic agents were significant risk factors for ONJ.

Free Research Field

医療薬学